<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-9957</journal-id>
<journal-title><![CDATA[Revista colombiana de Gastroenterología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Col Gastroenterol]]></abbrev-journal-title>
<issn>0120-9957</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Gastroenterología  ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-99572018000400437</article-id>
<article-id pub-id-type="doi">10.22516/25007440.314</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Helicobacter pylori : ¿cómo mejorar las terapias de erradicación?]]></article-title>
<article-title xml:lang="en"><![CDATA[How can Helicobacter pylori eradication therapies be improved?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morcillo Muñoz]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Otero Regino]]></surname>
<given-names><![CDATA[William]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Zuleta]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[Bogotá D. C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[Bogotá D. C.]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[Bogotá D. C]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>33</volume>
<numero>4</numero>
<fpage>437</fpage>
<lpage>447</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-99572018000400437&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-99572018000400437&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-99572018000400437&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Desde el descubrimiento de Helicobacter pylori, la erradicación del mismo ha sido un reto constante y el tratamiento ideal todavía no está disponible. La creciente resistencia del microorganismo a los antibióticos más frecuentemente utilizados es la circunstancia que más ha impactado en la eficacia de los diferentes esquemas. El objetivo del presente trabajo es revisar los aspectos generales de la infección por H. pylori, los aspectos básicos de los componentes de las terapias de erradicación, la nomenclatura de los distintos tratamientos, las características generales de los antibióticos y, finalmente, los tratamientos recomendados con base en las publicaciones recientes más importantes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Since the discovery of Helicobacter pylori (H. pylori), eradication has been a constant challenge, and an ideal treatment is not yet available. The increasing resistance of the microorganism to the most frequently used antibiotics has most impacted the effectiveness of the various schemes. The objectives of this work are to provide a general review of H. pylori infections and the nomenclature of the various treatments, discuss the basic issues and components of eradication therapies together with the general characteristics of antibiotics, and finally to recommend treatments based on in the most important recent publications.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Helicobacter]]></kwd>
<kwd lng="es"><![CDATA[resistencia]]></kwd>
<kwd lng="es"><![CDATA[inhibidores de la bomba de protones]]></kwd>
<kwd lng="es"><![CDATA[antibióticos]]></kwd>
<kwd lng="en"><![CDATA[Helicobacter]]></kwd>
<kwd lng="en"><![CDATA[resistance]]></kwd>
<kwd lng="en"><![CDATA[PPI]]></kwd>
<kwd lng="en"><![CDATA[antibiotics.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importancia de la proteína CagA en la infección por Helicobacter pylori]]></article-title>
<source><![CDATA[Rev. Col Gastroenterol]]></source>
<year>2009</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>388-95</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Caminos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phenotypic and Genotypic Analysis of Clarthromycin-Resistant Helicobacter pylori from Bogotá D.C., Colombia]]></article-title>
<source><![CDATA[J Microbiol]]></source>
<year>2013</year>
<volume>51</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>448-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori: Tratamiento actual. Un importante reto en gastroenterología]]></article-title>
<source><![CDATA[Rev Colomb Gastroenterol]]></source>
<year>2009</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>279-92</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cammarota]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sanguinetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Posteraro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2012</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>222-30</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hooi]]></surname>
<given-names><![CDATA[JKY]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Suen]]></surname>
<given-names><![CDATA[MMY]]></given-names>
</name>
<name>
<surname><![CDATA[Underwood]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Tanyingoh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2017</year>
<volume>153</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>420-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosme]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mendarte]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Salicio]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori]]></article-title>
<source><![CDATA[Clinical Microbiology and Infection]]></source>
<year>2013</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>379-83</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peleteiro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bastos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nuno]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2014</year>
<volume>59</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1698-709</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Axon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori and Public Health]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2014</year>
<volume>19</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>68-73</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedades relacionadas con la infección por Helicobacter pylori]]></article-title>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2015</year>
<volume>38</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>39-48</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedades relacionadas con la infección por Helicobacter pylori]]></article-title>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2014</year>
<volume>37</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>40-52</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1984</year>
<volume>1</volume>
<page-range>1311-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Steensma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shampo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Barry James Marshall-Discovery of Helicobacter pylori as a Cause of Peptic Ulcer]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2016</year>
<volume>91</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e67-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori: después de todo. Temas escogidos de gastroenterología]]></article-title>
<source><![CDATA[Asociación Colombiana de Gastroenterología]]></source>
<year>2007</year>
<page-range>43-56</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrego]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter prlori y enfermedades hematológicas]]></article-title>
<source><![CDATA[Rev Col Gastroenterol]]></source>
<year>2013</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>329-37</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mégraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bessède]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Varon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori infection and gastric carcinoma]]></article-title>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>2015</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>984-90</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits]]></article-title>
<source><![CDATA[Gastroenterol]]></source>
<year>2015</year>
<volume>148</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>719-31</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<collab>IARC Working Group on the Evaluation of Carcinogenic Risks to Humans</collab>
<article-title xml:lang=""><![CDATA[Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7-14 June 1994]]></article-title>
<source><![CDATA[IARC Monogr Eval Carcinog Risks Hum]]></source>
<year>1994</year>
<volume>61</volume>
<page-range>1-241</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Albis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sabbagh]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Erradicación del Helicobacter pylori: encuesta realizada por la Asociación Colombiana de Gastroenterología]]></article-title>
<source><![CDATA[Rev. Col Gastroenterol]]></source>
<year>2015</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-31</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Venerito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Selgrad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori infection: selected aspects in clinical management]]></article-title>
<source><![CDATA[Curr Opin Gastroenterol]]></source>
<year>2013</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>669-75</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tack]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kuipers]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[El-Omar]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Miura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Kyoto global consensus report on Helicobacter pylori gastritis]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2015</year>
<volume>64</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1353-67</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shiotani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical Aspects in Choosing a Helicobacter pylori Therapy]]></article-title>
<source><![CDATA[Gastroenterol Clin N Am]]></source>
<year>2015</year>
<volume>44</volume>
<page-range>519-35</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Fischbach]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori treatment in the era of increasing antibiotic resistance]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2010</year>
<volume>59</volume>
<page-range>1143-53</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Link]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Selgrad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori: perspectives and time trends]]></article-title>
<source><![CDATA[Nat Rev Gastroenterol Hepatol]]></source>
<year>2014</year>
<volume>11</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>628-38</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2014</year>
<volume>20</volume>
<numero>30</numero>
<issue>30</issue>
<page-range>10338-47</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugimoto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Furuta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2014</year>
<volume>20</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>6400-11</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furuta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection]]></article-title>
<source><![CDATA[Gastroenterol Clin N Am]]></source>
<year>2010</year>
<volume>39</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>465-80</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic treatment for Helicobacter pylori: Is the end coming?]]></article-title>
<source><![CDATA[World J Gastrointest Pharmacol Ther]]></source>
<year>2015</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>183-98</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furuta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ohashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kamata]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Takashima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kosuge]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kawasaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1998</year>
<volume>129</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1027-30</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Zhai]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials]]></article-title>
<source><![CDATA[PLOS ONE]]></source>
<year>2013</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2014</year>
<volume>59</volume>
<page-range>1235-43</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Echizen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2016</year>
<volume>55</volume>
<page-range>409-18</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hori]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Imanishi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matsukawa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tsukimi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nishida]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Arikawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2010</year>
<volume>335</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>231-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakurai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hibberd]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/ non-Japanese subjects]]></article-title>
<source><![CDATA[Clin Transl Gastroenterol]]></source>
<year>2015</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garnock-Jones]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vonoprazan: first global approval]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2015</year>
<volume>75</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>439-43</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murakami]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sakurai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shiino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Funao]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Asaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2016</year>
<volume>65</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1439-46</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2017</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>106-14</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Selgrad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori]]></article-title>
<source><![CDATA[Curr Opin Gastroentero]]></source>
<year>2014</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>589-95</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[McNicholl]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2017</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Riquelme]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Problem of Helicobacter pylori Resistance to Antibiotics: A Systematic Review in Latin America]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2014</year>
<volume>109</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>485-95</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori: tratamiento en 2018]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Temas Escogidos de Gastroenterología]]></source>
<year>2018</year>
<page-range>63-78</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thung]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Aramin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Vavinskaya]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Crowe]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review article: the global emergence of Helicobacter pylori antibiotic resistance]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2016</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>514-33</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horiki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Omata]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Uemura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ishii]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Iizuka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2009</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>86-90</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto de la resistencia de Helicobacter pylori a los antimicrobianos en la eficacia de la terapia triple estándar y en dos triples terapias con levofloxacina en pacientes colombianos]]></article-title>
<source><![CDATA[Gastroenterol Latinoam]]></source>
<year>2012</year>
<volume>23</volume>
<page-range>S35</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Liou]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence-based recommendations for successful Helicobacter pylori treatment]]></article-title>
<source><![CDATA[Expert Rev Gastroenterol Hepatol]]></source>
<year>2014</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-8.</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Dore]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori therapy: a paradigm shift]]></article-title>
<source><![CDATA[Expert Review of Anti-infective Therapy]]></source>
<year>2016</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>577-85</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly]]></article-title>
<source><![CDATA[Gastroenterol Clin North Am]]></source>
<year>2015</year>
<volume>44</volume>
<page-range>537-63</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trespalacios-Rangél]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo-Galvis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poutou-Piñales]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Rimbara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014)]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2016</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugimoto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sahara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ichikawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kagami]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Uotani]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Furuta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High Helicobacter pylori cure rate with sitafloxacin-based triple therapy]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2015</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>477-83</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcus]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Sachs]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eradication of Helicobacter pylori infection]]></article-title>
<source><![CDATA[Current gastroenterology reports]]></source>
<year>2016</year>
<volume>18</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>33</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keogan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Griffith]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current and Potential Applications of Bismuth-Based Drugs]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2014</year>
<volume>19</volume>
<page-range>15258-97</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Morain]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Kuipers]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Axon]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2017</year>
<volume>66</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-30</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Megraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Morain]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Atherton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Axon]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Bazzoli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2012</year>
<volume>61</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>646-64</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Infante]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Amador]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bermejo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bujanda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori]]></article-title>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2016</year>
<volume>39</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>697-721</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos]]></article-title>
<source><![CDATA[Rev Col Gastroenterol]]></source>
<year>2015</year>
<volume>30</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>17-33</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dore]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of bismuth in improving Helicobacter pylori eradication with triple therapy]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2016</year>
<volume>65</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>870-8</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Lian]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2015</year>
<volume>64</volume>
<page-range>1715-20</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gokcan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Oztas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Onal]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety]]></article-title>
<source><![CDATA[Clin Res Hepatol Gastroenterol]]></source>
<year>2016</year>
<volume>40</volume>
<page-range>124-31</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Morain]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Montague]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Challenges to Therapy in the Future]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2000</year>
<volume>5</volume>
<page-range>23-6</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Festa]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Andriulli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of antibiotic-resistant Helicobacter pylori]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1998</year>
<volume>339</volume>
<page-range>53</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crabol]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Catherinot]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Veziris]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifabutin: where do we stand in 2016?]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2016</year>
<volume>71</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1759-71</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Della Bruna]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schioppacassi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ungheri]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies]]></article-title>
<source><![CDATA[J Antibiot (Tokyo)]]></source>
<year>1983</year>
<volume>36</volume>
<page-range>1502-6</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review article: rifabutin in the treatment of refractory Helicobacter pylori infection]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2012</year>
<volume>35</volume>
<page-range>209-21</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread]]></article-title>
<source><![CDATA[Saudi J Gastroenterol]]></source>
<year>2012</year>
<volume>18</volume>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[HU]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Furazolidone , amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2009</year>
<volume>15</volume>
<page-range>860-4</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bismuth containing quadruple therapy for Helicobacter pylori: lessons from China]]></article-title>
<source><![CDATA[Eur J Gastroenterol Hepato]]></source>
<year>2013</year>
<volume>25</volume>
<page-range>1134-40</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohammadi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Attaran]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Malekzadeh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2017</year>
<volume>62</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1890-6</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[N-H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance]]></article-title>
<source><![CDATA[Front. Cell. Infect. Microbiol]]></source>
<year>2017</year>
<volume>7</volume>
<page-range>168</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimum duration of regimens for Helicobacter pylori eradication]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2013</year>
<volume>12</volume>
<page-range>CD008337</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chey]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Leontiadis]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
<name>
<surname><![CDATA[Howden]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACG clinical guideline: treatment of Helicobacter pylori infection]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2017</year>
<volume>112</volume>
<page-range>212-39</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fallone]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chiba]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[van Zanten]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fischbach]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Toronto consensus for the treatment of Helicobacter pylori infection in adults]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2016</year>
<volume>151</volume>
<page-range>51-69</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of Helicobacter pylori Infection in the proton pump Inhibitor era]]></article-title>
<source><![CDATA[Gastroenterol Clin N Am]]></source>
<year>2015</year>
<volume>44</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>507-18</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malfertheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mégraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Morain]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG)]]></article-title>
<source><![CDATA[Eur J Gastroenterol Hepatol]]></source>
<year>1997</year>
<volume>9</volume>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2014</year>
<volume>12</volume>
<page-range>177-86</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[PI]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2011</year>
<volume>16</volume>
<page-range>139-45</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Saabagh]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectiveness of a hibrid therapy in eradicating Helicobacter pylori in a Colombian population]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2016</year>
<volume>150</volume>
<page-range>S246</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ducoumau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bénéjat]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sifré]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Lehours]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mégraud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods]]></article-title>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>2016</year>
<volume>22</volume>
<page-range>715-8</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pretreatment Antimicrobial Susceptibility-Guided Vs. Clarithromycin-Based Triple Therapy for Helicobacter pylori Eradication in a Region With High Rates of Multiple Drug Resistance]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2014</year>
<volume>109</volume>
<page-range>1595-602</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Personalized therapy for Helicobacter pylori: influence of cyp2c19 genotype in first triple therapy]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trespalacios-Rangél]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo-Galvis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poutou-Piñales]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Rimbara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014)]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2016</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villoria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vergara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis: high dose proton pump inhibtor vs standard dose in triple therapy for Helicobacter pylori eradication]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>868-77</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Angel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Genta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>1997</year>
<volume>11</volume>
<page-range>529-32</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Erradicación de H pylori con Terapia Triple: Bismuto, Furazolidona, Tetraciclina]]></article-title>
<source><![CDATA[Acta Med Col]]></source>
<year>1996</year>
<volume>21</volume>
<page-range>218</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Some food additives, feed additives and naturally occurring substances]]></article-title>
<source><![CDATA[IARC Monogr Eval Carcinog Risk Chem Hum]]></source>
<year>1983</year>
<volume>31</volume>
<page-range>1-291</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sumano]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ocampo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barragán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation the carcinogenic effects of furazolidone and its metabolites in two fish species]]></article-title>
<source><![CDATA[Pharmacogenomics J]]></source>
<year>2004</year>
<volume>4</volume>
<page-range>24-8</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High efficacy of 14 -day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2010</year>
<volume>15</volume>
<page-range>233-8</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciccaglione]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Tavani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grossi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifabutin containing triple therapy and rifabutin with bismuth Containing quadruple therapy for third-line treatment of Helicobacter pylori infection: Two pilot studies]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2016</year>
<volume>21</volume>
<page-range>375-81</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Connor]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Vaira]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Morain]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of Helicobacter pylori infection 2014]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2014</year>
<volume>19</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>38-45</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Szajewska]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Horvath]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ko&#322;odziej]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2015</year>
<volume>41</volume>
<page-range>1237-45</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luther]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chey]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinician&#8217;s guide to salvage therapy for persistent Helicobacter pylori infection]]></article-title>
<source><![CDATA[Hosp Pract (1995)]]></source>
<year>2011</year>
<volume>39</volume>
<page-range>133-40</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yonezawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Osaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kamiya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biofilm Formation by Helicobacter pylori and its involvement for antibiotic resistance]]></article-title>
<source><![CDATA[Biomed Res Int 2015]]></source>
<year>2015</year>
<page-range>914791</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cammarota]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ianiro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bibbò]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Culture-guided treatment approach for Helicobacter pylori infection: Review of the literature]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2014</year>
<volume>20</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>5205-11</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cammarota]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Branca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ardito]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>817-20</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guide Regarding Choice of Second-line Therapy to Obtain a High Cumulative Cure Rate]]></article-title>
<source><![CDATA[Helicobacter]]></source>
<year>2012</year>
<volume>17</volume>
<page-range>243-5</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrego]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Trespalacios]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avances en la búsqueda de la vacuna contra Helicobacter pylori]]></article-title>
<source><![CDATA[MÉD.UIS]]></source>
<year>2017</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>111-20</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[XH]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>10002</numero>
<issue>10002</issue>
<page-range>1457-64</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sutton]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[t last, vaccine-induced protection against Helicobacter pylori]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>1002</numero>
<issue>1002</issue>
<page-range>1424-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
